- Fourth quarter net sales of $2.023 billion increased 4.3% and 4.9% on a constant currency1 basis
- Fourth quarter diluted earnings per share were $1.20; adjusted1 diluted earnings per share were $2.31
- Full-year net sales of $7.679 billion increased 3.8% and 4.8% on a constant currency1 basis
- Full-year diluted earnings per share were $4.43; adjusted1 diluted earnings per share were $8.00
- Company provides full-year 2025 financial guidance
WARSAW, Ind., Feb. 6, 2025 /PRNewswire/ — Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter and year ended December 31, 2024. The Company reported fourth quarter net sales of $2.023 billion, an increase of 4.3% over the prior year period, and an increase of 4.9% on a constant currency1 basis. Net sales for the full year were $7.679 billion, an increase of 3.8% over the prior year, and an increase of 4.8% on a constant currency1 basis. Net earnings for the fourth quarter were $239.4 million, or $462.4 million on an adjusted1 basis. For the full year, net earnings were $903.8 million, or $1.630 billion on an adjusted1 basis.
Diluted earnings per share were $1.20 for the fourth quarter, and adjusted1 diluted earnings per share were $2.31. Full-year diluted earnings per share were $4.43, and adjusted1 diluted earnings per share were $8.00.
“We are pleased with our fourth quarter results and strong performance to close 2024, delivering on our financial guidance and validating the solid work that the team is doing across the globe,” said Ivan Tornos, Zimmer Biomet’s President and Chief Executive Officer. “We have committed to diversifying our portfolio outside of core orthopedics and investing in attractive, higher-growth segments. Our recently announced agreement to acquire Paragon 28 marks a bold step towards executing on our diversification ambitions; once the transaction is closed, we expect our S.E.T. business to be larger than our Hip business, and to grow at a much faster pace.”
Recent Highlights
- Announced definitive agreement to acquire Paragon 28, Inc. (NYSE: FNA), a leading medical device company focused exclusively on the foot and ankle orthopedic segment, demonstrating Zimmer Biomet’s commitment to investing in higher growth end-markets with expansion into the ~$5 billion foot and ankle segment.
- Announced the U.S. Food and Drug Administration (FDA) Premarket Approval (PMA) for the Oxford® Cementless Partial Knee. Following more than 20 years of clinical experience and over 300,000 procedures performed across Canada, Europe, Middle East, Africa, and Asia, the Oxford Cementless Partial Knee is the only FDA-approved cementless partial knee implant in the U.S.
- Announced FDA 510(k) clearance for the OsseoFit™ Stemless Shoulder System for total shoulder replacement. This innovative implant is designed to match the natural humeral (upper shoulder bone) anatomy to optimize anatomical fit while maximizing preservation of healthy bone.
- Received CE Mark Certification for the Persona® Revision Knee System, building on Zimmer Biomet’s commitment to personalized solutions, providing more surgeons with advanced tools for revision knee arthroplasty.
- Welcomed Arnold Schwarzenegger as Chief Movement Officer. In this strategic role, Mr. Schwarzenegger will collaborate with Zimmer Biomet to motivate, engage and support individuals to increase mobility, maintain joint health and proactively incorporate movement into their daily routines to foster overall health and wellness and support the Company’s Direct-to-Patient efforts.
| ________ |
| 1 Reconciliations of these measures to the corresponding U.S. generally accepted accounting principles measures are included in this press release. |
Geographic and Product Category Sales
The following sales tables provide results by geography and product category for the three-month period and year ended December 31, 2024, as well as the percentage change compared to the applicable prior year period, on both a reported basis and a constant currency basis.
